APPENDIX B

Claim Limitation	Support in Adair Application
24. A humanized immunoglobulin having complementarity determining regions (CDRs) from a donor immunoglobulin and heavy and light chain variable region frameworks from human acceptor immunoglobulin heavy and light chains	See page 1, lines 5-16, and page 7, line 32, through page 8, line 21.
which humanized immunoglobulin specifically binds to an antigen with an affinity constant of at least 10^8 M^{-1}	See page 11, lines 27-30.
wherein said humanized immunoglobulin comprises amino acids from the donor immunoglobulin framework outside both the Kabat CDRs and the structural loop CDRs of the variable regions,	See page 6, lines 14-23, page 8, lines 13-16, and page 19, line 16, to page 20, line 15.
wherein the donor amino acids replace corresponding amino acids in the acceptor immunoglobulin heavy or light chain frameworks,	See page 6, line 12, to page 7, line 5.
and each of said donor amino acids is adjacent to a CDR in the donor immunoglobulin sequence	See page 11, lines 16-20, showing that homology is maximized between donor and acceptor sequences adjacent CDRs within acceptor framework. At page 6, lines 25-35, it is indicated that the heavy chain "framework comprises donor residues at at least one of positions 6, 23 and/or 24, 48 and/or 49...." In the heavy chain, Kabat CDR2 together with [Chothia] structural loop H2 extends from residues 50 to 65. Thus, residue 49 is immediately adjacent the beginning of this CDR2/H2 region.

or contributes to antigen binding as determined by X-ray crystallography.	Page 38, lines 1-12, and lines 23-38, and Figs. 3-4 of the application as filed reference residues that may "contribute to antigen binding" as determined using X-ray crystallography. Residues 6, 23,24, and 48 are identified in Figure 4.